Ulcerative colitis (UC) is a disease that causes long-term inflammation in the digestive tract, and many people with this condition require surgery to remove the colon and create a new J-pouch for stool. Some patients develop a problem called pouchitis, where this pouch becomes inflamed.
Official registry: https://clinicaltrials.gov/study/NCT07501078 · Muhammad N Aslam, MD · enrollment listed as 52
Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
If you join, the listed intervention(s) are Aquamin. The registry lists allocation as na. Ulcerative colitis (UC) is a disease that causes long-term inflammation in the digestive tract, and many people with this condition require surgery to remove the colon and create a new J-pouch for stool.
They plan to enroll about 52 people at Ann Arbor. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation
Interventions: Aquamin
Primary outcome (registry wording): Changes in Intestinal permeability assessed by urinary Lactulose/mannitol urinary ratio
Lauren Manning
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Aim: More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.
NCT02421705 · Official ClinicalTrials.gov record · KU Leuven
This study wants to estimate and compare the incidence of overall malignancy, serious infection, and opportunistic infections between new users of ustekinumab and new users of other biologic therapies among adult participants with Crohn's disease (CD) or ulcerative colitis (UC).
NCT04372108 · Official ClinicalTrials.gov record · Janssen Scientific Affairs, LLC
Inflammatory Bowel Diseases (IBDs), including ulcerative colitis and Crohn's disease (CD), constitute a group of debilitating chronic diseases that profoundly impact patient quality of life and incurs large costs in terms of treatment and lost productivity. Incidence of IBD is rising worldwide, and there is a pressing clinical need for development of new therapies.
NCT06006039 · Official ClinicalTrials.gov record · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary